Krajina: Austrália
Jazyk: angličtina
Zdroj: Department of Health (Therapeutic Goods Administration)
Cladribine
Orphan Australia Pty Ltd
Medicine Registered
LITAK ® - Consumer Medicine Information Page 1 of 4 _ _ LITAK ® 2 MG/ML SOLUTION FOR INJECTION _CLADRIBINE _ _ _ CONSUMER MEDICINE INFORMATION (CMI) WHAT IS THIS LEAFLET This leaflet answers some common questions about LITAK solution for injection. It does not contain all of the available information. All medicines have risks and benefits. Your doctor has weighed the risks of you being given LITAK against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT BEING GIVEN LITAK, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT IS LITAK USED FOR _ _ LITAK solution for injection is used to treat certain types of cancers; hairy cell leukaemia and lymphoplasmacytic lymphoma (also known as Waldenström’s Macroglobulinaemia). LITAK contains the active ingredient, cladribine. Cladribine belongs to a group of medicines called antineoplastic (cytotoxic, or chemotherapy agents). These agents are used to treat cancer. LITAK helps to stop the uncontrolled increase and abnormal growth of cancer cells. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY LITAK HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed LITAK for another use. LITAK is not addictive. BEFORE YOU ARE GIVEN IT LITAK solution for injection is not suitable for everyone. _WHEN YOU MUST NOT BE GIVEN IT _ _ _ DO NOT USE LITAK IF YOU ARE: • allergic to cladribine or any of the other ingredients listed at the end of this leaflet. Symptoms of an allergic reaction to LITAK may include shortness of breath, wheezing, difficulty breathing or a tight feeling in your chest; swelling of the face, Prečítajte si celý dokument
LITAK ® – Product Information Page 1 of 12 PRODUCT INFORMATION LITAK 2 MG/ML SOLUTION FOR INJECTION NAME OF DRUG Cladribine. C 10 H 12 ClN 5 O 3 = 285.7. CAS Registry Number: 4291-63-8 DESCRIPTION LITAK (cladribine) is a synthetic antineoplastic agent for subcutaneous injection and intravenous infusion. Cladribine is a chlorinated purine nucleoside analogue (cytostatic agent) with the chemical name 2-chloro-2’-deoxy- β-D-adenosine or 2-chloro-6-amino- 9-(2-deoxy- β-D-erythropento-furanosyl)-purine. LITAK solution for injection is presented as clear, colourless, sterile, preservative-free, isotonic solution. LITAK is available in single-use vials containing 10 mg of cladribine in 5 mL of solution, ready-to-use for subcutaneous injection without dilution or can be diluted for intravenous infusion. Each mL of the solution contains 2 mg of cladribine and 9 mg of sodium chloride. LITAK also contains water for injections to make the solution up to 5 mL. The product may also contain sodium hydroxide or hydrochloric acid to adjust the pH. The pH range of LITAK solution is 6.5 - 7.5. PHARMACOLOGY PHARMACODYNAMIC PROPERTIES LITAK contains cladribine as active ingredient, a purine nucleoside analogue acting as an antimetabolite. The single substitution of chlorine for hydrogen at position 2 distinguishes cladribine from its natural counterpart 2'-deoxyadenosine and renders the molecule resistant to deamination by adenosine deaminase. LITAK ® – Product Information Page 2 of 12 _Cellular resistance and sensitivity _ Cladribine is a prodrug, which is taken up rapidly into cells after parenteral administration, and is phosphorylated intracellularly to the active nucleotide 2- chlorodeoxyadenosine-5’-triphosphate (CdATP), initially by deoxycytidine k Prečítajte si celý dokument